{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:26:10Z","timestamp":1779927970126,"version":"3.53.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.vaccine.2021.02.026","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T01:00:06Z","timestamp":1615510806000},"page":"1997-2004","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Invasive pneumococcal disease due to 22F and 33F in England: A tail of two serotypes"],"prefix":"10.1016","volume":"39","author":[{"given":"Zahin","family":"Amin-Chowdhury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Groves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen L.","family":"Sheppard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Litt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman K.","family":"Fry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamez N.","family":"Ladhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vaccine.2021.02.026_b0005","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/clinids\/7.2.133","article-title":"Invasive pneumococcal infections: incidence, predisposing factors, and prognosis","volume":"7","author":"Burman","year":"1985","journal-title":"Rev Infect Dis."},{"issue":"3","key":"10.1016\/j.vaccine.2021.02.026_b0010","doi-asserted-by":"crossref","first-page":"E545","DOI":"10.9778\/cmajo.20160035","article-title":"The epidemiology of invasive pneumococcal disease in older adults from 2007 to 2014 in Ontario, Canada: a population-based study","volume":"4","author":"Desai","year":"2016","journal-title":"CMAJ Open"},{"issue":"3","key":"10.1016\/j.vaccine.2021.02.026_b0015","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00937-20","article-title":"A new pneumococcal capsule type, 10D, is the 100th serotype and has a large cps fragment from an oral streptococcus","volume":"11","author":"Ganaie","year":"2020","journal-title":"mBio"},{"issue":"3","key":"10.1016\/j.vaccine.2021.02.026_b0020","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1128\/CMR.00024-15","article-title":"Pneumococcal capsules and their types: past, present, and future","volume":"28","author":"Geno","year":"2015","journal-title":"Clin Microbiol Rev"},{"issue":"10","key":"10.1016\/j.vaccine.2021.02.026_b0025","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1473-3099(11)70090-1","article-title":"Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study","volume":"11","author":"Miller","year":"2011","journal-title":"Lancet Infect Dis."},{"issue":"1","key":"10.1016\/j.vaccine.2021.02.026_b0030","first-page":"27","article-title":"A review of pneumococcal vaccines: current polysaccharide vaccine recommendations and future protein antigens","volume":"21","author":"Daniels","year":"2016","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.vaccine.2021.02.026_b0035","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1473-3099(15)70044-7","article-title":"Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study","volume":"15","author":"Waight","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"32","key":"10.1016\/j.vaccine.2021.02.026_b0040","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1016\/j.vaccine.2019.06.071","article-title":"Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: the indirect cohort design, 2006\u20132018","volume":"37","author":"Andrews","year":"2019","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2021.02.026_b0045","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1473-3099(18)30052-5","article-title":"Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000\u201317: a prospective national observational cohort study","volume":"18","author":"Ladhani","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2021.02.026_b0050","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa043","article-title":"Characteristics of invasive pneumococcal disease (IPD) caused by emerging serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) in England; prospective observational cohort study, 2014\u201318","author":"Amin-Chowdhury","year":"2020","journal-title":"Clin Infect Dis: An Off Publ Infect Dis Soc Am"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2021.02.026_b0055","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1097\/INF.0000000000000083","article-title":"Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type nasopharyngeal carriage","volume":"33","author":"Fleming-Dutra","year":"2014","journal-title":"Pediat Infect Dis J"},{"issue":"1","key":"10.1016\/j.vaccine.2021.02.026_b0060","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.vaccine.2013.05.005","article-title":"Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects","volume":"32","author":"Davis","year":"2013","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2021.02.026_b0065","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/14760584.2020.1711055","article-title":"The long search for a serotype independent pneumococcal vaccine","volume":"19","author":"Converso","year":"2020","journal-title":"Expert Rev Vaccines"},{"issue":"45","key":"10.1016\/j.vaccine.2021.02.026_b0070","doi-asserted-by":"crossref","first-page":"6883","DOI":"10.1016\/j.vaccine.2018.02.113","article-title":"Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants","volume":"36","author":"Greenberg","year":"2018","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2021.02.026_b0075","doi-asserted-by":"crossref","first-page":"e0177113","DOI":"10.1371\/journal.pone.0177113","article-title":"Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis","volume":"12","author":"Balsells","year":"2017","journal-title":"PLoS ONE"},{"issue":"8","key":"10.1016\/j.vaccine.2021.02.026_b0080","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S2213-2600(17)30110-8","article-title":"Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study","volume":"5","author":"Savulescu","year":"2017","journal-title":"Lancet Resp Med"},{"issue":"3","key":"10.1016\/j.vaccine.2021.02.026_b0085","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1128\/JCM.01917-12","article-title":"Changes in molecular epidemiology of streptococcus pneumoniae causing meningitis following introduction of pneumococcal conjugate vaccination in England and Wales","volume":"51","author":"Pichon","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2021.02.026_b0090","doi-asserted-by":"crossref","first-page":"e2477","DOI":"10.7717\/peerj.2477","article-title":"Whole genome sequencing of Streptococcus pneumoniae: development, evaluation and verification of targets for serogroup and serotype prediction using an automated pipeline","volume":"4","author":"Kapatai","year":"2016","journal-title":"PeerJ"},{"key":"10.1016\/j.vaccine.2021.02.026_b0095","doi-asserted-by":"crossref","first-page":"e3571","DOI":"10.7717\/peerj.3571","article-title":"Clinical streptococcal isolates, distinct from Streptococcus pneumoniae, but containing the \u03b2-glucosyltransferase tts gene and expressing serotype 37 capsular polysaccharide","volume":"5","author":"Sheppard","year":"2017","journal-title":"PeerJ"},{"key":"10.1016\/j.vaccine.2021.02.026_b0100","unstructured":"Public Health England. Pneumococcal: The Green Book, chapter 25; 2013. [Available from: https:\/\/www.gov.uk\/government\/publications\/pneumococcal-the-green-book-chapter-25."},{"key":"10.1016\/j.vaccine.2021.02.026_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2019.07.057","article-title":"Diversity of serotype replacement after pneumococcal conjugate vaccine implementation in Europe","volume":"213","author":"Levy","year":"2019","journal-title":"J Pediatr"},{"issue":"1","key":"10.1016\/j.vaccine.2021.02.026_b0110","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/648593","article-title":"Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine","volume":"201","author":"Pilishvili","year":"2010","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2021.02.026_b0115","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1086\/592972","article-title":"Emergence of Streptococcus pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in Cleveland, Ohio, in relation to introduction of the protein-conjugated pneumococcal vaccine","volume":"47","author":"Jacobs","year":"2008","journal-title":"Clin Infect Dis: An Off Pub Infect Dis Soc Am"},{"issue":"4","key":"10.1016\/j.vaccine.2021.02.026_b0120","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/01.inf.0000207484.52850.38","article-title":"Streptococcus pneumoniae serogroups 15 and 33: an increasing cause of pneumococcal infections in children in the United States after the introduction of the pneumococcal 7-valent conjugate vaccine","volume":"25","author":"Gonzalez","year":"2006","journal-title":"Pediatr Infect Dis J"},{"issue":"12","key":"10.1016\/j.vaccine.2021.02.026_b0125","doi-asserted-by":"crossref","first-page":"e0226353","DOI":"10.1371\/journal.pone.0226353","article-title":"The shifting epidemiology and serotype distribution of invasive pneumococcal disease in Ontario, Canada, 2007\u20132017","volume":"14","author":"Wijayasri","year":"2019","journal-title":"PloS one"},{"key":"10.1016\/j.vaccine.2021.02.026_b0130","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.3389\/fmicb.2016.02099","article-title":"Whole-genome sequencing for surveillance of invasive pneumococcal diseases in Ontario, Canada: rapid prediction of genotype, antibiotic resistance and characterization of emerging serotype 22F","volume":"7","author":"Deng","year":"2016","journal-title":"Front Microbiol"},{"issue":"23","key":"10.1016\/j.vaccine.2021.02.026_b0135","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1016\/j.vaccine.2016.03.058","article-title":"Invasive Streptococcus pneumoniae in Canada, 2011\u20132014: characterization of new candidate 15-valent pneumococcal conjugate vaccine serotypes 22F and 33F","volume":"34","author":"Golden","year":"2016","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2021.02.026_b0140","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1093\/jac\/dkv061","article-title":"Assessment of multidrug resistance, clonality and virulence in non-PCV-13 Streptococcus pneumoniae serotypes in Canada, 2011\u201313","volume":"70","author":"Golden","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.vaccine.2021.02.026_b0145","doi-asserted-by":"crossref","first-page":"e39150","DOI":"10.1371\/journal.pone.0039150","article-title":"Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes","volume":"7","author":"van Hoek","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2021.02.026_b0150","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3389\/fmicb.2020.00309","article-title":"Clinical relevance and molecular pathogenesis of the emerging serotypes 22F and 33F of streptococcus pneumoniae in Spain","volume":"11","author":"Sempere","year":"2020","journal-title":"Front Microbiol"},{"issue":"3","key":"10.1016\/j.vaccine.2021.02.026_b0155","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/21645515.2019.1568159","article-title":"A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants","volume":"15","author":"Rupp","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"10.1016\/j.vaccine.2021.02.026_b0160","doi-asserted-by":"crossref","first-page":"e0195799","DOI":"10.1371\/journal.pone.0195799","article-title":"Pneumococcal carriage in children and their household contacts six years after introduction of the 13-valent pneumococcal conjugate vaccine in England","volume":"13","author":"Southern","year":"2018","journal-title":"PLoS ONE"},{"issue":"9","key":"10.1016\/j.vaccine.2021.02.026_b0165","doi-asserted-by":"crossref","DOI":"10.3390\/genes10090687","article-title":"The genomics of streptococcus pneumoniae carriage isolates from UK children and their household contacts, pre-PCV7 to post-PCV13","volume":"10","author":"Sheppard","year":"2019","journal-title":"Genes"},{"issue":"5","key":"10.1016\/j.vaccine.2021.02.026_b0170","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jinf.2018.06.004","article-title":"The relative invasive disease potential of Streptococcus pneumoniae among children after PCV introduction: a systematic review and meta-analysis","volume":"77","author":"Balsells","year":"2018","journal-title":"J Infec"},{"issue":"42","key":"10.1016\/j.vaccine.2021.02.026_b0175","doi-asserted-by":"crossref","first-page":"6201","DOI":"10.1016\/j.vaccine.2019.08.048","article-title":"Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults","volume":"37","author":"Thompson","year":"2019","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2021.02.026_b0180","doi-asserted-by":"crossref","first-page":"18977","DOI":"10.1038\/s41598-020-75691-5","article-title":"Divergent serotype replacement trends and increasing diversity in pneumococcal disease in high income settings reduce the benefit of expanding vaccine valency","volume":"10","author":"L\u00f8chen","year":"2020","journal-title":"Sci Rep"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21001742?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21001742?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:56:26Z","timestamp":1759402586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21001742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":36,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0264410X21001742"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.02.026","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Invasive pneumococcal disease due to 22F and 33F in England: A tail of two serotypes","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.02.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}